Bifogade filer
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data highlighting how nadunolimab, an IL1RAP-targeting antibody currently in phase II clinical development, may induce antitumor activity in pancreatic cancer by blocking fibrosis. The data will be presented as a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego and were generated in a collaboration with Nordic Bioscience A/S and the group of Dr. Marcus Järås at Lund University.
“These new data are really promising and strengthen our confidence of nadunolimab as future therapy for pancreatic cancer” said Göran Forsberg, CEO of Cantargia.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with poor survival prognosis. Nadunolimab is currently in phase II clinical development in first line PDAC and has shown pronounced effects including a much longer survival than expected from historical controls. One factor that significantly contributes to the poor treatment response in PDAC is the high abundance of tumor-supporting stroma, driven by the excessive activity of cancer-associated fibroblasts (CAFs). The new data now show that in pancreatic cancer-associated fibroblasts, interleukin-1alpha (IL-1alpha) and IL-1beta both induce formation of type III collagen (as measured by PRO-C3), a biomarker which has been found to correlate with poor survival in PDAC. Similarly, formation of type III collagen could also be induced by pancreatic cancer cells when co-cultured with pancreatic CAFs. Notably, addition of nadunolimab to the in vitro co-cultures potently blocked the induction of type III collagen formation. Thus, the new data strengthen the role of IL-1alpha and IL-1beta in pancreatic tumor fibrosis and highlight the potential for nadunolimab to counter the detrimental, fibrotic microenvironment in PDAC tumors.
“One of the clinical challenges in treating pancreatic cancer relates to the tumor promoting fibrosis, a hallmark of this disease. Nadunolimab’s ability to block this fibrosis is very promising and gives a strong support to the clinical and translational results we have to date” said David Liberg, CSO of Cantargia.
The data was generated in collaboration with Nordic Bioscience A/S and Lund University and will be presented by Dr. Nicholas Willumsen from Nordic Bioscience at the AACR Annual Meeting April 5-10 in San Diego, California. The abstract has now been published on the conference website (link).
Title: ILRAP blockade mediates anti-fibrotic effects in pancreatic cancer-associated fibroblasts
Session Title: The Tumor Microenvironment as a Drug Target
Session Date and Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM
Published Abstract Number: 2895
After the conference, the poster will be available at Cantargia’s web page (link).